financetom
EWTX
financetom
/
Healthcare
/
EWTX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Edgewise Therapeutics, Inc.EWTX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
1.11B
Revenue (ttm)
n/a
Net Income (ttm)
-133.81M
Shares Out
95.21M
EPS (ttm)
-1.45
PE Ratio
n/a
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
300,548
Open
11.48
Previous Close
11.57
Day's Range
11.28 - 11.89
52-Week Range
10.60 - 38.12
Beta
0.33
Analysts
Buy
Price Target
40.38 (+245.72%)
Earnings Date
May 8, 2025
Description >

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders.

In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.

The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Latest News >
Copyright 2023-2025 - www.financetom.com All Rights Reserved